Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

DYAX $25.75 9.0000 +53.73%
IMDZ $27.22 6.1100 +28.94%
BCRX $9.99 0.9600 +10.63%
ARWR $7.43 0.6600 +9.75%
ADXS $15.49 1.0500 +7.27%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

VBLT $4.63 -0.5700 -10.96%
CERU $8.05 -0.9600 -10.65%
ARGS $8.17 -0.7400 -8.31%
ZIOP $10.10 -0.6700 -6.22%
CPXX $2.34 -0.1300 -5.26%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next > | Last >>

Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Lung Cancer and Melanoma

(Merck) Mar 31, 2015 - Syndax Pharmaceuticals, Inc., and Merck announced today that they have entered into a clinical trial collaboration to evaluate the safety and efficacy of combining Syndax’s entinostat, an investigational epigenetic therapy, with Merck’s KEYTRUDA® (pembrolizumab), the first anti-PD-1 therapy approved in the United States.
read corporate press release 



Report Shows Progress in America's War on Cancer

(WebMD/HealthDay News) Mar 30, 2015 - America is making slow but steady progress against cancer, with a continuing decline in cancer deaths, according to a new report.
read article 



New Cancer Drugs 'Vastly Overestimated', Says Contrarian Analyst

(Reuters) Mar 31, 2015 - A hot new class of drugs designed to help the body's own immune system fend off cancer by blocking a protein called PD-1 is going to be big - but not nearly as big as investors think, according to a new analysis.
read article 



New Data Helps Doctors Zero in on Breast Cancer Risks, Treatments

(CBS News) Mar 30, 2015 - Newly published nationwide data may help doctors identify which patients are at most risk for each type of breast cancer and which treatments may be most effective.
read article 



FDA Grants Amgen Priority Review for Kyprolis® (Carfilzomib) Supplemental New Drug Application for the Treatment of Relapsed Multiple Myeloma

(Yahoo! Finance) Mar 30, 2015 – Amgen today announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) of Kyprolis® (carfilzomib) for Injection for the treatment of patients with relapsed multiple myeloma who have received at least one prior therapy.
read article 



Opinion: Trying to Fool Cancer

(New York Times) Mar 28, 2015 - Which mutations are evil, and which are innocent?
read article 



Women with Ovarian Cancer Gain Extra Months with Addition of Drug to Standard Chemotherapy

(SGO) Mar 28, 2015 - In a study presented today at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer, overall survival for women who received standard chemotherapy treatment plus bevacizumab was a median five months longer than for women who received the standard chemotherapy treatment alone.
read press release 



Immunotherapy Delays Recurrence for Stage III and IV Ovarian Cancers

(SGO) Mar 28, 2015 - An experimental immunotherapy is in the works that can target an individual woman’s tumor and extend the time period between initial treatment and the cancer’s return.
read press release 



Google to Develop Robot Surgical Devices in Pact With J&J

(Washington Post/Bloomberg) Mar 27, 2015 - The companies will explore ways to add advanced imaging and sensors to surgical tools, helping doctors during operations. The partnership is through the life-sciences division of Google X labs, the company’s research unit that has funded projects such as self-driving cars.
read article (free registration required) 



Pay for Performance Extends to Health Care in Experiment in New York

(New York Times) Mar 30, 2015 - Accountable care organizations are still relatively new in health care, and New York’s experiment is one of many underway.
read article 



UnitedHealth to Buy Pharmacy Benefit Firm Catamaran for $12.8 Billion

(Reuters) Mar 30, 2015 - Health insurer UnitedHealth Group Inc agreed to buy Catamaran Corp in a deal worth about $12.8 billion to boost its pharmacy benefit business as it competes with bigger rivals such as Express Scripts Holdings Co.
read article 



Teva Buying Auspex for $3.2 Billion

(ABC News/Associated Press) Mar 30, 2015 - Teva Pharmaceutical Industries Ltd. is buying Auspex Pharmaceuticals Inc. for about $3.2 billion in a move to strengthen its position on central nervous system condition treatments.
read article 



In Swansong, FDA Chief Defends Drug Approval Process

(Reuters) Mar 27, 2015 - In her final speech after six years as commissioner of the U.S. Food and Drug Administration, Dr. Margaret Hamburg defended the agency's drug approval standards against critics seeking weaker regulatory standards.
read article 



Makers of Generic Drugs Challenge FDA Plan for Updated Warnings

(New York Times) Mar 27, 2015 - The generics industry has proposed that the federal agency take full responsibility for altering labels whenever health risks are discovered rather than expecting companies to take the initiative.
read article 



IMS Health Study: Reimbursement Approaches Based on Cost-Per-Quality-Adjusted-Life-Year Measures Rather Than Drug Effectiveness May Limit Access to Innovative Cancer Treatments

(Yahoo! Finance) Mar 27, 2015 - Even as the surge in innovative oncology medicines yields new therapeutic options for a growing number of cancer patients, different approaches to reimbursement by health systems across the globe are likely having an impact both on patient access to transformative treatments and overall care, according to a new report from the IMS Institute for Healthcare Informatics.
read article 



Senate Delays Vote on SGR Repeal; Ongoing Action Needed

(ASCO in Action) Mar 27, 2015 - ASCO is extremely disappointed that the Senate failed to act on the Medicare Access and CHIP Reauthorization Act of 2015 (H.R. 2)--legislation that would eliminate the perennial threat and uncertainty that the Sustainable Growth Rate (SGR) formula creates for physicians and Medicare beneficiaries--before adjourning for a two-week Spring recess.
read article 



The World's 50 Greatest Leaders: #42 Richard Pazdur

(Fortune) Mar 29, 2015 - Rarely does one hear anybody celebrate the FDA. But lately the agency’s gatekeeper for cancer drugs is getting nearly universal praise for his effort to speed promising medications to market.
read article 



Letters: FDA Is Systematically Screening For Safe Sunscreens

(Wall Street Journal) Mar 30, 2015 - Your editorial “Washington’s Skin Cancer Hostages” (March 14) is wrong about the FDA’s review of sunscreen ingredients changes made by the Sunscreen Innovation Act.
read article (paid subscription required) 



Letters: Ovarian Cancer: Learning the Risks

(New York Times) Mar 30, 2015 - When Angelina Jolie Pitt first spoke out about having a mutation in her BRCA1 genes, the number of women who sought genetic testing more than doubled.
read article 



Living with Cancer: Clinical Trials Looking for Patients

(New York Times/Well blog) Mar 26, 2015 - A drug obtained through a clinical trial appears to have extended my life. So why do many trials fail to enroll sufficient patients?
read article 



Review: In 'Cancer: The Emperor of All Maladies,' Battling an Opportunistic Killer

(New York Times) Mar 27, 2015 - Early in Monday’s first installment of PBS’s “Cancer: The Emperor of All Maladies,” a statistic about cancer’s toll in the United States is offered to convey the magnitude of the subject.
read article 



Chatting With Anne Parker: A Patient's View On How Cancer Care Has Changed Since The 1960s

(Forbes) Mar 29, 2015 - Anne Parker is a remarkable person, one of the first cancer patients in North America to have learned she carries a BRCA gene mutation.
read article 



Medical Bills Linger, Long After Cancer Treatment Ends

(NPR/Shots blog) Mar 27, 2015 - A woman's family is stuck with medical charges for care she received after being diagnosed with pancreatic cancer. Negotiating relief from the bills has become a part-time job for her daughter.
read article 



Landmark OVA1 Cost-Effectiveness Analysis Compared to Current Standard of Care for Ovarian Cancer Presented at American College of Medical Quality Conference

(TheStreet) Mar 27, 2015 - Vermillion, Inc. today announced initial results from a cost-effectiveness analysis study which will be presented today at the Annual Meeting of the American College of Medical Quality in Alexandria, Virginia.
read article 



Zytiga Label to Include Overall Survival Data

(Monthly Prescribing Reference) Mar 30, 2015 - The Food and Drug Administration (FDA) has approved a label update for Zytiga (abiraterone acetate; Janssen Biotech) to include statistically significant results in combination with prednisone for the treatment of chemotherapy-naive men with metastatic castration-resistant prostate cancer (mCRPC).
read article (free registration required)